Neoantigen Peptide Synthesis Service
GenScript’s Neoantigen Peptide Synthesis Service supports everything from functional screening of neoantigen candidates for TCR therapy to clinical stage vaccine immunogenicity testing.
Receive your quote directly from the manufacturer.
Neoantigen peptides are usually expressed on the cell surface, and arise due to single amino acid deletions, insertions, or substitutions. Because of this, they vary in length, charge, and hydrophobicity, leading to difficulty in synthesis and purification. With over 20 years experience, GenScript delivers reliable and quality peptides with over 95% success rate and duperior immunogenicity.
Accelerate neoantigen-based immunotherapy development for cancer treatment
Overcome challenges in neoantigen-based immunotherapy development and leverage synthetic peptides for cancer treatment.
Synthetic peptides are indispensable across all phases of immunotherapy, from discovery and development to manufacturing. Identifying neoantigen peptides is essential for creating personalized cancer vaccines and T cell therapies, driving the advancement of highly targeted and effective treatments.
This eBook aims to address the significant challenges faced by scientists and laboratory professionals in the timely generation of reagents essential for accelerating patient therapies.
Download to learn more about:
- The applications of synthetic peptides
- Advancing shared neoantigen-based immunotherapies
- Validating neoantigen-reactive T-cell receptors
- Bioinformatics tools for peptide synthesis
- Rapid cGMP peptide manufacturing
- Neoantigen peptide synthesis for precision therapeutics
- Developing personalized neoantigen vaccines
Advanced mRNA and LNP Strategies for CRISPR Delivery
Delve into exciting new technologies pushing the boundaries in research and advancing the development of novel therapeutics. Through a series of engaging presentations by experts in the fields of synthetic peptide technologies, genome editing, and drug development, our speakers will dive into the latest advances and trends in neoantigen peptide discovery for personalized cancer immunotherapy, the promising potential of mRNA-based tools for gene editing, and the innovative world of self-amplifying RNAs as a cutting-edge modality, shaping the next generation of RNA vaccines.
Recent breakthroughs in RNA therapeutics have unveiled the incredible potential of mRNA-based tools for gene editing. Lipid nanoparticles (LNPs) can co-encapsulate mRNA and guide RNA for highly efficient delivery both to cells in vitro and in vivo.
GenScript’s cutting-edge platform produces top-quality mRNA with enhanced expression, reduced immunogenicity, and extended half-life. Paired with a novel guide RNA design, this guarantees exceptional editing efficiency with low off-target effects.
In this webinar, Dr. Shambhavi Shubham, field application scientist at GenScript will share how the company harnesses advanced formulations of CRISPR enzymes like Cas9 and Cas12, and Prime editing to achieve powerful gene editing. To further elevate performance, GenScript leverages advanced strategies, including customizing CRISPR mRNAs with tissue-specific UTRs, optimizing IVT conditions to reduce dsRNA, and using codon optimization and circular RNA forms. Moreover, to meet precise delivery needs, GenScript technology leverages antibody-decorated or SORT LNPs.
Join us and learn how GenScript’s advanced platform serves the needs of researchers and biopharmaceutical companies by driving the rapid development of ground-breaking therapeutics and propelling genetics research forward.
Key learning objectives
- Understand the mechanisms and potential of mRNA-based tools for gene editing
- Discover the use of lipid nanoparticles (LNPs) for co-encapsulating mRNA and guide RNA, facilitating efficient delivery in vitro and ex vivo
- Gain insights into advanced formulations incorporating CRISPR mRNA like Cas9 and Cas12, as well as prime editing
- Explore strategies for achieving targeted delivery through antibody-decorated LNPs or SORT LNPs to increase efficiency at specific sites
Who should attend?
Audiences working on mRNA, gene editing, and LNP delivery solutions
Interested in this webinar? Explore the other webinars in this series on Applications and Challenges of Neoantigen Peptides in Personalized Cancer Vaccines and Self-Amplifying RNA in Vaccines and Beyond
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes
Applications and Challenges of Neoantigen Peptides in Personalized Cancer Vaccines
Delve into exciting new technologies pushing the boundaries in research and advancing the development of novel therapeutics. Through a series of engaging presentations by experts in the fields of synthetic peptide technologies, genome editing, and drug development, our speakers will dive into the latest advances and trends in neoantigen peptide discovery for personalized cancer immunotherapy, the promising potential of mRNA-based tools for gene editing, and the innovative world of self-amplifying RNAs as a cutting-edge modality, shaping the next generation of RNA vaccines.
This webinar introduces the fundamentals of neoantigen peptide discovery and its importance in personalized cancer immunotherapy. Dr. Shan She, Senior Global Product Manager at GenScript will discuss advances and current trends in neoantigen peptide applications, emphasizing their potential to improve the specificity and effectiveness of cancer vaccines.
This session will also explore GenScript's innovative technologies and one-stop solutions for neoantigen research, offering insights into successful case studies and practical applications. Ideal for researchers in academia and biopharmaceutical companies, this webinar will provide a comprehensive overview of neoantigen peptide research and therapeutic applications.
Join us and gain deep insight into how GenScript's high-quality services support this field.
Key learning objectives
- Learn the history of neoantigen peptides
- Explore neoantigen peptide market research
- Understand neoantigen peptide classification and challenges
- Discover GenScript’s customized service offerings and see how they can support your research
Who should attend?
- Researchers in academia and biopharmaceutical companies
Interested in this webinar? Explore the other webinars in this series on Advanced mRNA and LNP Strategies for CRISPR Delivery and Self-Amplifying RNA in Vaccines and Beyond
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes
Self-Amplifying RNA in Vaccines and Beyond
Delve into exciting new technologies pushing the boundaries in research and advancing the development of novel therapeutics. Through a series of engaging presentations by experts in the fields of synthetic peptide technologies, genome editing, and drug development, our speakers will dive into the latest advances and trends in neoantigen peptide discovery for personalized cancer immunotherapy, the promising potential of mRNA-based tools for gene editing, and the innovative world of self-amplifying RNAs as a cutting-edge modality, shaping the next generation of RNA vaccines.
The remarkable success of SARS-CoV2 vaccines has brought to light the incredible potential of in vitro transcribed RNA as a ground-breaking vaccine platform. Unlike traditional vaccines, RNA vaccines offer the exciting possibility of swift development and production, enabling rapid responses to emerging diseases. A recent breakthrough in RNA vaccine technology is the development of self-amplifying RNAs, which not only generate higher levels of immunogens but also require lower doses compared with conventional RNA vaccines.
This webinar will delve into the innovative world of self-amplifying RNAs as a cutting-edge RNA modality. Throughout the session, we will explore what self-amplifying RNAs are, how they differ from conventional RNA and their potential impact on shaping the next generation of RNA vaccines and other therapeutic applications.
Join Mark Shulewitz, PhD, senior scientist at GenScript for an enlightening discussion on the future of vaccine technology.
Key learning objectives
- Learn how RNA is used in vaccines and other therapeutic applications such as protein replacement therapy
- Discover what modalities of RNA are currently being explored for therapeutic applications
- Explore the shortcomings of conventional RNA and how self-amplifying RNA addresses some of these issues
- Gain insight into the latest developments in self-amplifying RNAs
Who should attend?
- Experienced RNA users interested in learning more about self-amplifying RNA
- Absolute beginners interested in learning about self-amplifying RNA
- Researchers interested in RNA vaccine development and protein replacement therapies
- Life science, biopharma and pharmaceutical professionals interested in cutting-edge technologies that have multiple applications in therapeutic development and basic life science research
- Developers of traditional vaccines looking for a new approach
Interested in this webinar? Explore the other webinars in this series on Applications and Challenges of Neoantigen Peptides in Personalized Cancer Vaccines and Advanced mRNA and LNP Strategies for CRISPR Delivery
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes
Drug Discovery & Development Scientists’ Choice Award 2025 winners announced
Agilent, Tecan, and Cytiva among those recognized
